Abstract:Background Surgical resection is often the preferred treatment for non-small cell lung cancer (NSCLC) patients. Predictive biomarkers after surgery can help monitoring and treating patients promptly, so as to improve the clinical outcome. In this study, we evaluated one potential candidate biomarker, the folate receptor-positive circulating tumor cell (FR + CTC), by investigating its prognostic and predictive significance in NSCLC patients who underwent surgery. Methods In this prospective, observational study, we enrolled NSCLC patients who were eligible to receive surgery. Prior to operation, peripheral blood was collected from each patient for an FR + CTC analysis. FR + CTCs were isolated by negative enrichment using immunomagnetic beads to deplete leukocytes and then quantitatively detected by a ligand-targeted polymerase chain reaction (PCR) method. These patients were then given standard care and were actively followed up for seven years. At the end of the follow-up period, the association between the FR + CTC level and the prognosis in these patients was evaluated. Results Overall, preoperative FR + CTC level was not significantly different among NSCLC patients with adenocarcinoma or non-adenocarcinoma subtypes ( P = 0.24). However, between patients with low- and high-risk pathological adenocarcinoma subtypes, the preoperative FR + CTC level was significantly different ( P = 0.028). Further, patients with lower preoperative FR + CTC level had longer relapse-free survival (RFS) and overall survival (OS) than those with higher preoperative FR + CTC level (RFS: not reached vs. 33.3 months, P = 0.018; OS: not reached vs. 72.0 months, P = 0.13). In a multivariate COX regression analysis, FR + CTC level (HR = 4.10; 95% CI, 1.23–13.64; P =0.022) and pathological stage (HR = 3.16; 95% CI, 1.79–10.14; P = 0.0011) were independent prognostic factors of RFS. Moreover, FR + CTC level together with adenocarcinoma subtypes provided additional information on risk for disease recurrence compared with FR + CTC or adenocarcinoma subtype alone. Conclusion Our study demonstrated that the preoperative FR + CTC level was a potential predictor for the prognosis of NSCLC patients underwent surgery. Further, when preoperative FR + CTC level is considered together with primary tumor proliferation characteristics, its prognostic value supplements that of these conventional pathological features.

Overexpression Of Fadd And Bcl-Xs Proteins As Novel Prognostic Biomarkers For Surgically Resected Non-Small Cell Lung Cancer

Sideroflexin1 As a Novel Tumor Marker Independently Predicts Survival in Lung Adenocarcinoma

Expression of FADD and Its Relation to Apoptosis in Non-Small Cell Lung Cancer

Prognostic Significance and Immune Correlates of FADD in Penile Squamous Cell Carcinoma.

Prognostic Value of PD-L1 Expression in Combination with CD8+ TILs Density in Patients with Surgically Resected Non-Small Cell Lung Cancer.

A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.

Elevated FUS/TLS Expression is Negatively Associated with E-cadherin Expression and Prognosis of Patients with Non-Small Cell Lung Cancer

Expression of DR5 and C‑flip Proteins As Novel Prognostic Biomarkers for Non‑small Cell Lung Cancer Patients Treated with Surgical Resection and Chemotherapy

Enhanced Expression of FGF19 Predicts Poor Prognosis in Patients with Non-Small Cell Lung Cancer

Prognostic Significance Of Mcl-1 In Advanced Non-Small Cell Lung Cancer Patients

Prognostic Assessment of Apoptotic Gene Polymorphisms in Non-Small Cell Lung Cancer in Chinese

Upregulated FADD is associated with poor prognosis, immune exhaustion, tumor malignancy, and immunotherapy resistance in patients with lung adenocarcinoma

Clinical Significance of PD-L1 Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer.

[Expression of Fas and P53 Protein in Resected Non-Small Cell Lung Cancer and Its Prognostic Significance].

Prognostic impact of Fas-associated death domain, a key component in death receptor signaling, is dependent on the presence of lymph node metastasis in head and neck squamous cell carcinoma.

Expression of Bcl-2 is a Favorable Prognostic Biomarker in Lung Squamous Cell Carcinoma

Expression and Predictive Significance of FHL1 and SLIT3 in Surgically Resected Lung Adenocarcinoma

Interstitial Tumor-Associated Macrophages Combined with Tumor-Derived Colony-Stimulating Factor-1 and Interleukin-6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer.

Preoperative Folate Receptor-Positive Circulating Tumor Cell Level Is a Prognostic Factor of Long Term Outcome in Non-Small Cell Lung Cancer Patients

Prognostic Role of Twist, Slug, and Foxc2 Expression in Stage I Non–Small-Cell Lung Cancer after Curative Resection

[Expression and Clinical Significance of Apoptosis-Related Oncogenes in Stage I-II Non-Small Cell Lung Cancer].